摘要
目的 探讨首发精神分裂症患者血清烯醇化酶 (NSE)含量与利培酮临床疗效的关系。方法 对74例首次发作的精神分裂症患者 ,应用利培酮治疗 8周。于治疗前及治疗后用PANSS量表评定疗效 ,用TESS量表评定不良反应 ,用放射免疫法 (RIA)检测血清NSE含量。结果 治疗前首发精神分裂症患者血清NSE含量明显高于对照组 (P <0 .0 5 ) ;与PANSS量表呈正相关 (r =0 .5 84 ,P <0 .0 5 ) ,治疗后显著降低 ,但仍高于对照组 (P <0 .0 5 )。结论 首发精神分裂症患者的血清NSE含量升高 ,随病情的好转而降低 ,且与病情的严重程度呈正相关。
Objective To explore the relationship between the serum neuron specific enolase (NSE) level and the clinical effects of risperidone in first episode schizophrenia.Methods Seventy four first episode schizophenia were treated with risperidone for 8 weeks.The patients were rated with PANSS and TESS.The serum NSE level was mearsured with RIA before and after treatment.Results The serum NSE level in first episode schizophenia was higher than that in the control group( P <0.05).Before treatment,the serum NSE level was positively related to the total score of PANSS(r=0.584, P <0.05).After treatment,the serum NSE level was decreased,but higher than that in control group ( P <0.05).Conclusion The serum NSE level was higher in the first episode schizophrenia,and decreased with the symptoms improved.The serum NSE level was positively related to the severity.
出处
《山东精神医学》
2003年第3期133-134,共2页
Shangdong Archives of Psychiatry
